During 2009, 28% of patients enrolled on studies managed by the Protocol Office participated in investigator-initiated research, with either external or internal peer-review (Figure 14). These figures do not include national cooperative group or pharmaceutical studies, even when the principal investigator may have contributed to study design. As previously noted, these studies often use investigational drugs and may incorporate combined modality therapy as well as laboratory correlates, with a greater impact on overall protocol resources. Additionally, many require filing and holding an IND. The scope of responsibilities for the Clinical Research Coordinator (CRC) and Data Manager (DM) are generally more detailed for these studies in comparison to cooperative group or industry-sponsored studies. Protocol Office staff are involved in the initial review and evaluation of the protocol as well as the content and design of the data collection forms used in conjunction with the protocol. In addition, the CRC and DM are much more involved with the local recruitment of patients for investigator-initiated trials, as well as a greater level of involvement with the coordination of biospecimen collection for local pharmacokinetic analysis. The Protocol Office compiles and tabulates data summary reports, such as toxicity tables, to facilitate presentation at Phase l-ll Committee meetings, which provide data and safety monitoring for these studies, The Protocol Office staff are responsible for study initiation, data monitoring, protocol changes, dissemination of study information, and preparation of safety reports and annual reports. The CRC and DM function as a team in conjunction with the Principal Investigator to evaluate protocols and the data collected for completeness, accuracy, and protocol compliance in accordance with federal regulations and guidelines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
7P30CA006927-50
Application #
8475351
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$69,824
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Austin, Steven R; Wong, Yu-Ning; Uzzo, Robert G et al. (2015) Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care 53:e65-72
Bassi, Daniel E; Cenna, Jonathan; Zhang, Jirong et al. (2015) Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6). Mol Carcinog 54:1122-31
Sherman, Kerry A; Miller, Suzanne M; Roussi, Pagona et al. (2015) Factors predicting adherence to risk management behaviors of women at increased risk for developing lymphedema. Support Care Cancer 23:61-9
Eytan, Esther; Wang, Kexi; Miniowitz-Shemtov, Shirly et al. (2014) Disassembly of mitotic checkpoint complexes by the joint action of the AAA-ATPase TRIP13 and p31(comet). Proc Natl Acad Sci U S A 111:12019-24
Johnson, Matthew E; Handorf, Elizabeth A; Martin, Jeffrey M et al. (2014) Postmastectomy radiation therapy for T3N0: a SEER analysis. Cancer 120:3569-74
Gabitova, Linara; Gorin, Andrey; Astsaturov, Igor (2014) Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res 20:28-34
Silverman, Diana; Ruth, Karen; Sigurdson, Elin R et al. (2014) Skin involvement and breast cancer: are T4b lesions of all sizes created equal? J Am Coll Surg 219:534-44
Gupta, Sapna; Melnyk, Stepan B; Kruger, Warren D (2014) Cystathionine *-synthase-deficient mice thrive on a low-methionine diet. FASEB J 28:781-90
Simhan, Jay; Smaldone, Marc C; Egleston, Brian L et al. (2014) Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int 114:216-20
Gowrishankar, Banumathy; Ibragimova, Ilsiya; Zhou, Yan et al. (2014) MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 15:329-41

Showing the most recent 10 out of 475 publications